fbpx
February 28, 2025

FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use

FDA reviewed five observational studies4-8 and two meta-analyses of placebo-controlled trials9,10 to examine the risk of cardiovascular events associated with testosterone replacement therapy (TRT). The five […]
February 28, 2025

FDA Roundup: February 28, 2025

For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0